Daniel Shepshelovich, MD

Internal Medicine
Hospital Medicine
Profile Headshot

Overview

Dr. Daniel Shepshelovich is an expert on evidence-based medicine for hospitalized medical patients and the ways medical evidence is collected and interpreted by medical professional societies and regulators. His overarching career goals are to contribute to the scientific foundations of medicine, provide professional and compassionate patient care, and help train the next generation of academic hospitalists.

Dr. Shepshelovich was born in Israel, where he attended medical school and completed his training in Internal Medicine. He completed a clinical and research fellowship focused on early drug development and health policy research at the Princess Margaret Cancer Centre at Toronto, Ontario. In 2023, he joined the faculty of Division of General Medicine in the Department of Medicine at Columbia University Medical Center.

Dr. Shepshelovich is a dedicated researcher with more than 90 peer-reviewed publications, many in influential journals. Dr. Shepshelovich’s has contributed to better understanding of regulatory drug approval and post-marketing surveillance, and identified ways to further improve these processes. His research continues with a focus on improving medical and regulatory decision-making.

Academic Appointments

  • Assistant Professor of Medicine at CUMC

Languages

  • Hebrew
  • Russian

Gender

  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Research

Selected Publications

  1. Moshkovits I, Shepshelovich D.
    Emergency Use Authorizations of Medical Products for COVID-19: a Cross-Sectional Study.
    JAMA Intern Med. 2022 Feb 1;182(2):228-229.
  2. Tau N, Shepshelovich D
    Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications.
    JAMA Intern Med. 2020 Nov 1;180(11):1420-1426.
  3. Tau N, Yahav D, Shepshelovich D.
    Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration: A Cohort Study.
    Ann Intern Med. 2020 Sep 15;173(6):445-449. 
  4. Yahav D, Tau N, Shepshelovich D
    Assessment of data supporting the efficacy of new antibiotics for treating infections caused by multidrug resistant bacteria.
    Clin Infect Dis. 2021 Jun 1;72(11):1968-1974. 
  5. Tau N, Shochat T, Gafter-Gvili A, Tibau A, Amir E, Shepshelovich D.
    Association Between Data Sources and US Food and Drug Administration Drug Safety Communications.
    JAMA Intern Med. 2019 Nov 1;179(11):1590-1592.
  6. Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E.
    Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. 
    J Clin Oncol. 2018 Jun 20;36(18):1798-1804.
For a complete link of publications, please visit PubMed (nih.gov)